1. 358 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3. (13th November 2020) Authors: Vergote, I; Salutari, V; Cibula, D; Korach, J; Samartzis, EP; Sehouli, J; Fossati, R; Martin, AG; Tsibulak, I; Slomovitz, B; Coleman, R; Monk, B; Thaker, P; O'Malley, D Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study. (1st November 2019) Authors: Vergote, I; Copeland, L; Monk, B; Coleman, R; Cibula, D; Sehouli, J; Samartzis, EP; Madry, R; González Martin, A; Korach, J; Salutari, V; Witteveen, PO; O'Malley, D Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗